Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer;Real-world data from 10,000 patients reinforce industry-leading sensitivity;Data presented for a new NeXT Personal feature for monitoring resistance mutations FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.Neoadjuvant Monitoring in Colorectal Cancer. A highlight was the oral podium presentation of the NEOPRISM-CRC trial, delivered by Dr. Jiang from the University College London, which utilized NeXT Personal to monitor patients with high-risk stage I
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026Business Wire
- Personalis to Participate in the 25th Annual Needham Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Personalis to Participate in the 25th Annual Needham Virtual ConferenceBusiness Wire
- Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 [Yahoo! Finance]Yahoo! Finance
PSNL
Earnings
- 2/26/26 - Beat
PSNL
Sec Filings
- 4/8/26 - Form SCHEDULE
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- PSNL's page on the SEC website